| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377556 | Bioorganic & Medicinal Chemistry Letters | 2007 | 6 Pages |
Abstract
Inhibition of the glycine transporter GlyT1 is a potential strategy for the treatment of schizophrenia. A novel series of GlyT1 inhibitors and their structure–activity relationships (SAR) are described. Members of this series are highly potent and selective transport inhibitors which are shown to elevate glycine levels in cerebrospinal fluid.
Graphical abstractA novel series of GlyT1 inhibitors and their structure–activity Relationships (SAR) are described. Members of this series are highly potent and selective transport inhibitors which are shown to elevate glycine levels in cerebrospinal fluid.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Magnus W. Walter, Beth J. Hoffman, Kimberly Gordon, Kirk Johnson, Patrick Love, Matthew Jones, Teresa Man, Lee Phebus, Jon K. Reel, Helene C. Rudyk, Harlan Shannon, Kjell Svensson, Hong Yu, Matthew J. Valli, Warren J. Porter,